选择性CBP/EP300代体抑制剂:对抗TNF-α驱动炎症的新型表观遗传工具
Katherine A Gosselé1,2, Irene Latino3, Eleen Laul1
1Department of Chemistry, University of Zurich, Zurich CH-8057, Switzerland.
JACS Au
|June 27, 2025
概括
针对CBP/EP300基因的新抑制剂通过阻断关键信号通路来减少炎症. 这些发现为自身免疫性疾病提供了有希望的治疗策略,例如由瘤缩因子α驱动的类风湿性关节炎.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 瘤亡因子α (TNF-α) 在自身免疫性疾病中驱动炎症.
- 在免疫反应中CBP/EP300基因 (BRDs) 的作用尚未完全理解.
- 针对细胞因子表达的表观遗传调节器是一种治疗策略.
研究的目的:
- 研究CBP/EP300-BRDs在免疫反应中的作用.
- 为了开发选择性的CBP/EP300-BRD抑制剂.
- 评估这些抑制剂在TNF-α介导炎症中的治疗潜力.
主要方法:
- 高通量片段对接以识别抑制剂.
- 在体外测试以评估细胞因子表达和NFκB信号传递.
- 在体内小鼠模型评估抗炎作用.
主要成果:
- 确定了选择性的CBP/EP300-BRD抑制剂.
- 抑制剂通过阻断NFκB信号来降低TNF-α驱动的细胞因子表达.
- 在体内研究表明,细胞因子分泌和免疫细胞迁移减少.
结论:
- CBP/EP300-BRDs是对自身免疫性疾病的有希望的治疗点.
- 开发的抑制剂显示出抗炎作用.
- 这些抑制剂可以补充TNF-α介导疾病的治疗方法,如类风湿性关节炎.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
239
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
239
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
277
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
277
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
NF-κB-dependent Signaling Pathway
7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


